{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:44:49Z","timestamp":1791315889567,"version":"4.3.1"},"reference-count":217,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1378\/chest.126.3_suppl.188s","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:47:46Z","timestamp":1095792466000},"page":"188S-203S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":808,"special_numbering":"S","title":["Heparin and Low-Molecular-Weight Heparin"],"prefix":"10.1016","volume":"126","author":[{"given":"Jack","family":"Hirsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Raschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.3_suppl.188S_bib1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","article-title":"The thromboplastic action of cephalin","volume":"41","author":"McLean","year":"1916","journal-title":"Am J Physiol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1152\/ajplegacy.1939.125.4.683","article-title":"The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin","volume":"125","author":"Brinkhous","year":"1939","journal-title":"Am J Physiol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/00365516809076981","article-title":"Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis","volume":"21","author":"Abildgaard","year":"1968","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib4","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"837","article-title":"The heparin-antithrombin system: a natural anticoagulant mechanism","author":"Rosenberg","year":"1994"},{"key":"10.1378\/chest.126.3_suppl.188S_bib5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1073\/pnas.76.3.1218","article-title":"Correlation between structure and function of heparin","volume":"76","author":"Rosenberg","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.188S_bib6","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1073\/pnas.76.7.3198","article-title":"Structure of the antithrombin-binding site of heparin","volume":"76","author":"Lindahl","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.188S_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj1970599","article-title":"The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence","volume":"97","author":"Casu","year":"1981","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1749-6632.1981.tb29770.x","article-title":"Structural studies on a biologically active hexasaccharide obtained from heparin","volume":"370","author":"Choay","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1378\/chest.126.3_suppl.188S_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0037-1614445","article-title":"Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty","volume":"81","author":"Vuillemenot","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib10","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood.V91.11.4197","article-title":"Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide","volume":"91","author":"Herbert","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib11","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib12","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for the prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0049-3848(76)90105-5","article-title":"Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration","volume":"9","author":"Andersson","year":"1976","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib15","first-page":"12","article-title":"Pharmacology of low molecular weight heparins","volume":"16","author":"Harenberg","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(00)84041-0","article-title":"The molecular weight range of commercial heparin preparations","volume":"51","author":"Johnson","year":"1976","journal-title":"Carbohydr Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib17","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0006-291X(76)90558-1","article-title":"The separation of active and inactive forms of heparin","volume":"69","author":"Lam","year":"1976","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1378\/chest.126.3_suppl.188S_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0049-3848(76)90105-5","article-title":"Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration","volume":"9","author":"Andersson","year":"1976","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib19","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0021-9258(18)34900-7","article-title":"Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma","volume":"257","author":"Tollefsen","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.CIR.99.5.682","article-title":"Vasoflux, a new anticoagulant with a novel mechanism of action","volume":"99","author":"Weitz","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib21","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1016\/S0021-9258(18)90755-6","article-title":"Extension and structural variability of the antithrombin-binding sequence in heparin","volume":"259","author":"Lindahl","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1042\/bj2180725","article-title":"Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4","volume":"218","author":"Lane","year":"1984","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.78.2.829","article-title":"Multiple functional domains of the heparin molecule","volume":"78","author":"Oosta","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.188S_bib24","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1016\/S0021-9258(17)43920-2","article-title":"A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin","volume":"258","author":"Nesheim","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1042\/bj2430579","article-title":"The inhibition of thrombin-dependent feedback reactions is critical to the expression of anticoagulant effects of heparin","volume":"243","author":"Ofosu","year":"1987","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj2570143","article-title":"Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa","volume":"257","author":"Ofosu","year":"1989","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-0038-1646990","article-title":"The mode of action of heparin in plasma","volume":"60","author":"Beguin","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0609.1971.tb01976.x","article-title":"Inhibition of thrombin-induced aggregation of human platelets in heparin","volume":"8","author":"Eika","year":"1971","journal-title":"Scand J Haematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib29","first-page":"259","article-title":"Bleeding associated with antithrombotic therapy","volume":"17","author":"Kelton","year":"1980","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1172\/JCI109661","article-title":"Effect of heparin and heparin fractions on platelet aggregation","volume":"65","author":"Salzman","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2141.1977.tb00666.x","article-title":"Impairment by heparin of primary haemostasis and platelet (14C)5-hydroxytryptamine release","volume":"36","author":"Heiden","year":"1977","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0049-3848(86)90094-0","article-title":"Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect","volume":"43","author":"Fernandez","year":"1986","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1749-6632.1989.tb22507.x","article-title":"Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits","volume":"556","author":"Blajchman","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"10.1378\/chest.126.3_suppl.188S_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0049-3848(82)90006-8","article-title":"Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction","volume":"27","author":"Ockelford","year":"1982","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/265625a0","article-title":"Suppression by heparin of smooth muscle cell proliferation in injured arteries","volume":"265","author":"Clowes","year":"1977","journal-title":"Nature"},{"key":"10.1378\/chest.126.3_suppl.188S_bib36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V86.4.1368.bloodjournal8641368","article-title":"The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria","volume":"86","author":"Shaughnessy","year":"1995","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0037-1615222","article-title":"The effects of standard and low molecular weight heparin on bone nodule formation in vitro","volume":"80","author":"Bhandari","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib38","doi-asserted-by":"crossref","first-page":"11256","DOI":"10.1016\/S0021-9258(18)33750-5","article-title":"Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin: possible role of a platelet endoglycosidase","volume":"257","author":"Castellot","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib40","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0049-3848(85)90244-0","article-title":"Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration","volume":"39","author":"Bara","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM198902093200604","article-title":"Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction","volume":"320","author":"Turpie","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0038-1647289","article-title":"Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis: a randomized clinical trial","volume":"64","author":"Pini","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.53.4.691","article-title":"Heparin kinetics in venous thrombosis and pulmonary embolism","volume":"53","author":"Hirsh","year":"1976","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0167-4889(85)90177-6","article-title":"Binding and endocytosis of heparin by human endothelial cells in culture","volume":"845","author":"Barzu","year":"1985","journal-title":"Biochim Biophys Acta"},{"key":"10.1378\/chest.126.3_suppl.188S_bib47","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1172\/JCI115198","article-title":"Heparin inhibition of von Willebrand factor-dependent platelet functionin vitroandin vivo","volume":"87","author":"Sobel","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib48","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.V60.6.1251.1251","article-title":"Kinetics of intravenously administered heparin in normal humans","volume":"60","author":"de Swart","year":"1982","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib49","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.0954-6820.1963.tb17446.x","article-title":"The elimination from plasma of intravenous heparin: an experimental study on dogs and humans","volume":"173","author":"Olsson","year":"1963","journal-title":"Acta Med Scand"},{"key":"10.1378\/chest.126.3_suppl.188S_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/clpt.1982.16","article-title":"Heparin kinetics determined by three assay methods","volume":"31","author":"Bjornsson","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.188S_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0049-3848(78)90271-2","article-title":"Binding of heparin on the surface of cultured human endothelial cells","volume":"12","author":"Glimelius","year":"1978","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0049-3848(78)90087-7","article-title":"Vascular sequestration of heparin","volume":"12","author":"Mahadoo","year":"1977","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1042\/bj1390699","article-title":"Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterization of the enzyme","volume":"139","author":"Friedman","year":"1974","journal-title":"Biochem J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib54","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0049-3848(79)90004-5","article-title":"Catabolism of low-dose heparin in man","volume":"14","author":"Dawes","year":"1979","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib55","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight based heparin dosing nomogram versus a standard care nomogram: a randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib56","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00804-4","volume":"36","author":"Antman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib57","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(99)00351-4","article-title":"1999 update: ACC\/AHA guidelines for the management of patients with acute myocardial infarction: a report of the ACC\/AHA Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)","volume":"34","author":"Ryan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib58","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib59","series-title":"Heparin: chemical and biological properties clinical applications","first-page":"517","article-title":"Heparin-induced bleeding","author":"Levine","year":"1989"},{"key":"10.1378\/chest.126.3_suppl.188S_bib60","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(86)91421-2","article-title":"Heparin doses and major bleedings","volume":"1","author":"Morabia","year":"1986","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib61","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes","volume":"90","author":"Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIA Investigators","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib62","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/01.CIR.90.4.1624","article-title":"Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial","volume":"90","author":"Antman","year":"1994","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib63","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","author":"The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIB Investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib64","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib65","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib66","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0002-9343(87)90004-0","article-title":"Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy","volume":"82","author":"Landefeld","year":"1987","journal-title":"Am J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib67","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/archinte.1996.00440140067006","article-title":"The effectiveness of implementing the weight-based heparin nomogram as a practice guideline","volume":"156","author":"Raschke","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib69","first-page":"782","article-title":"College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.188S_bib71","first-page":"530","article-title":"Laboratory monitoring of heparin: effect of reagents and instruments on the activated partial thromboplastin time","volume":"76","author":"Brandt","year":"1981","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archinte.161.3.385","article-title":"Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin","volume":"161","author":"Bates","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ajcp\/93.5.684","article-title":"Comparison of two aPTT methods of monitoring heparin therapy","volume":"93","author":"Zanke","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib74","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1001\/archinte.1997.00440420107010","article-title":"Inability of the activated partial thromboplastin time to predict heparin levels","volume":"157","author":"Baker","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib75","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/ajcp\/74.5.668","article-title":"Heparin and the activated partial thromboplastin time: a difference between thein-vitroandin-vivoeffects and implications for the therapeutic range","volume":"74","author":"Bain","year":"1980","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jcp.49.1.10","article-title":"Wide variability in the sensitivity of aPTT reagents for monitoring of heparin dosage","volume":"49","author":"Kitchen","year":"1996","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ajcp\/89.1.19","article-title":"The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer","volume":"89","author":"Shojania","year":"1988","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajcp\/110.2.173","article-title":"Comparing different lots of activated partial thromboplastin time reagent","volume":"110","author":"Rosborough","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib79","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/ajhp\/55.19.2002","article-title":"Establishing an institution-specific therapeutic range for heparin","volume":"55","author":"Volles","year":"1998","journal-title":"Am J Health Syst Pharm"},{"key":"10.1378\/chest.126.3_suppl.188S_bib80","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/ajcp\/108.6.662","article-title":"Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients","volume":"108","author":"Rosborough","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib81","first-page":"804","article-title":"Apparent heparin resistance from elevated factor VIII during pregnancy","volume":"96","author":"Raschke","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib82","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1515\/CCLM.1998.168","article-title":"Evaluation of the activated partial thromboplastin time sensitivity to heparin using five commercial reagents: Implications for therapeutic monitoring","volume":"36","author":"Manzato","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib83","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1650358","article-title":"The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays","volume":"75","author":"Kitchen","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib84","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1592\/phco.19.11.922.31573","article-title":"Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration","volume":"19","author":"Koerber","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.188S_bib85","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archinte.1991.00400020085018","article-title":"A standard heparin nomogram for the management of heparin therapy","volume":"151","author":"Cruickshank","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib86","doi-asserted-by":"crossref","first-page":"720","DOI":"10.7326\/0003-4819-138-9-200305060-00008","article-title":"Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin","volume":"138","author":"Raschke","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib87","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/000331979905001001","article-title":"Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis","volume":"50","author":"Belcaro","year":"1999","journal-title":"Angiology"},{"key":"10.1378\/chest.126.3_suppl.188S_bib88","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib89","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","article-title":"Low-molecular-weight heparin in the treatment of patients with venous thromboembolism","volume":"337","author":"The Columbus Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib90","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0038-1647660","article-title":"A randomized trial of subcutaneous low molecular weight heparin compared to intravenous unfractionated heparin in the treatment of deep venous thrombosis","volume":"65","author":"Duroux","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0038-1650553","article-title":"Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep venous thrombosis","volume":"76","author":"Fiessinger","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib92","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1055\/s-0037-1613886","article-title":"Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis","volume":"83","author":"Harenberg","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib93","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM199204093261502","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thombosis","volume":"326","author":"Hull","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.160.2.229","article-title":"Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism","volume":"160","author":"Hull","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib95","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","article-title":"Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home","volume":"334","author":"Koopman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib96","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","article-title":"A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis","volume":"334","author":"Levine","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0038-1648836","article-title":"Comparison of one-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis","volume":"72","author":"Lindmarker","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2796.1996.18845000.x","article-title":"A multicentre comparison of once-daily subcutaneous dalteparin and continuous intravenous heparin in the treatment of deep vein thrombosis","volume":"240","author":"Luomanmaki","year":"1996","journal-title":"J Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib99","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib101","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archinte.1993.00410130045005","article-title":"Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis","volume":"153","author":"Simonneau","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib102","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism","volume":"337","author":"Simonneau","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib103","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/01.CIR.93.5.870","article-title":"Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial","volume":"93","author":"Granger","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib104","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1055\/s-0038-1645678","article-title":"Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples","volume":"63","author":"van den Besselaar","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib107","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archinte.1997.00440280157015","article-title":"Management of iliofemoral thrombosis in a pregnant patient with heparin resistance","volume":"157","author":"Anand","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib108","series-title":"Hemostasis and thrombosis: basic principles and clinical practice","first-page":"1346","article-title":"Treatment of venous thromboembolism","author":"Hirsh","year":"1994"},{"key":"10.1378\/chest.126.3_suppl.188S_bib109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.1983.123","article-title":"Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin","volume":"34","author":"Whitfield","year":"1983","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.188S_bib110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins: An important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib111","first-page":"463","article-title":"Kaolin partial thromboplastin time: High levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants","volume":"70","author":"Edson","year":"1967","journal-title":"J Lab Clin Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib112","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/0140-6736(92)92935-9","article-title":"Heparin resistance after aprotinin","volume":"340","author":"Fisher","year":"1992","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib113","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0002-8703(05)80172-3","article-title":"Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality","volume":"119","author":"Becker","year":"1990","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib114","first-page":"1849","article-title":"Heparin-nitroglycerin interaction [letter]","volume":"121","author":"Raschke","year":"1991","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib115","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex-vivoandin-vitroevidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin","volume":"71","author":"Young","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib116","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells","volume":"93","author":"Visentin","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib117","first-page":"247","article-title":"Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V79.1.1.1","article-title":"Low molecular weight heparin","volume":"79","author":"Hirsh","year":"1992","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib119","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(98)09233-2","article-title":"New antithrombotic agents","volume":"353","author":"Hirsh","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2141.1973.tb01662.x","article-title":"Factor Xainactivation by antithrombin III: evidence for biological stabilization of factor Xaby factor V-phospholipid complex","volume":"24","author":"Marciniak","year":"1973","journal-title":"Br J Hematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib121","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0006-291X(79)91283-X","article-title":"The effects of phospholipid and factor Vaon the inhibition of factor Xaby antithrombin III","volume":"90","author":"Walker","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1378\/chest.126.3_suppl.188S_bib122","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1016\/S0021-9258(17)35610-7","article-title":"Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4","volume":"261","author":"Lane","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib123","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib124","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1073\/pnas.86.10.3619","article-title":"Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy","volume":"86","author":"Hogg","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.188S_bib125","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1074\/jbc.274.10.6226","article-title":"Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyst inhibition by antithrombin and heparin cofactor II","volume":"274","author":"Becker","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib126","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI114272","article-title":"Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties","volume":"84","author":"Bar-Shavit","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.126.3_suppl.188S_bib127","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.79.3.657","article-title":"Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor","volume":"79","author":"Heras","year":"1989","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0038-1645195","article-title":"The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits","volume":"63","author":"Agnelli","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effect of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures inpatients with acute myocardial ischaemia without ST elevation: a randomised trial","volume":"353","author":"Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib130","series-title":"AHFS drug information 1999","first-page":"1265","article-title":"Protamine Sulfate: Antiheparin agents 20:12.08","year":"1999"},{"key":"10.1378\/chest.126.3_suppl.188S_bib131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM197607152950318","article-title":"Protamine sulfate and fish allergy [letter]","volume":"295","author":"Caplan","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib132","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/01.CIR.70.5.788","article-title":"Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization","volume":"70","author":"Stewart","year":"1984","journal-title":"Circulation"},{"key":"10.1378\/chest.126.3_suppl.188S_bib133","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/0310057X9902700314","article-title":"Recent experiences with hexadimethrine for neutralizing heparin after cardiopulmonary bypass","volume":"27","author":"Cooney","year":"1999","journal-title":"Anaesth Intensive Care"},{"key":"10.1378\/chest.126.3_suppl.188S_bib134","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1213\/00000539-199608000-00004","article-title":"Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass","volume":"83","author":"Kikura","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib135","first-page":"670","article-title":"In vitroreversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients","volume":"79","author":"Despotis","year":"1994","journal-title":"Anesth Analg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib136","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/01.CIR.91.8.2188","article-title":"Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans","volume":"91","author":"Dehmer","year":"1995","journal-title":"Circulation"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.188S_bib137","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/00005344-199600001-00012","article-title":"Restoration of the normal coagulation process: advances in therapies to antagonize heparin","volume":"27","author":"D'Ambra","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib138","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/039139889702000308","article-title":"The use of heparin removal device: a valid alternative to protamine","volume":"20","author":"Hendrikx","year":"1997","journal-title":"International J Artif Organs"},{"key":"10.1378\/chest.126.3_suppl.188S_bib139","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/00003246-199806000-00035","article-title":"Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device: an alternative to protamine","volume":"26","author":"Tao","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib140","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0741-5214(97)70018-1","article-title":"A novel protamine variant reversal of heparin anticoagulation in human bloodin vitro","volume":"26","author":"Hulin","year":"1997","journal-title":"J Vasc Surg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib141","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0038-1648001","article-title":"Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection","volume":"35","author":"Johnson","year":"1976","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib142","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood.V59.6.1239.1239","article-title":"The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins in rabbits","volume":"59","author":"Carter","year":"1982","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib143","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0049-3848(85)90202-6","article-title":"The effects of heparin fragments of different molecular weight in experimental thrombosis and haemostasis","volume":"38","author":"Bergqvist","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib144","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib145","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0038-1646593","article-title":"Unfractionated heparin and CY216: pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa: effects of intravenous and subcutaneous injection in rabbits","volume":"61","author":"Briant","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib146","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0049-3848(86)90340-3","article-title":"Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers","volume":"42","author":"Bratt","year":"1986","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib147","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0038-1651070","article-title":"Effect of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers","volume":"57","author":"Matzsch","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib148","first-page":"65","article-title":"Pharmacokinetics of low molecular weight heparins","volume":"543","author":"Bara","year":"1988","journal-title":"Acta Chir Scand"},{"key":"10.1378\/chest.126.3_suppl.188S_bib149","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.1987.tb03100.x","article-title":"ORG 10172: a low molecular weight heparinoid anticoagulant with a long half life in man","volume":"23","author":"Bradbrook","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib151","doi-asserted-by":"crossref","first-page":"10081","DOI":"10.1016\/S0021-9258(19)70431-1","article-title":"The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin","volume":"255","author":"Jordan","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib152","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/bj1930395","article-title":"The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin","volume":"193","author":"Holmer","year":"1981","journal-title":"Biochem J"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.188S_bib153","first-page":"1","article-title":"Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties","volume":"16","author":"Holmer","year":"1986","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.188S_bib154","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1073\/pnas.80.18.5460","article-title":"Heparin-catalyzed inhibitor\/protease reactions: kinetic evidence for a common mechanism of action of heparin","volume":"80","author":"Griffith","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.126.3_suppl.188S_bib155","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0021-9258(18)33162-4","article-title":"Two-substrate reaction models for the heparin-catalyzed bovine antithrombin\/protease reaction","volume":"258","author":"Pletcher","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib156","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0006-291X(79)90260-2","article-title":"Highly active heparin species with multiple binding sites for antithrombin","volume":"86","author":"Rosenberg","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1378\/chest.126.3_suppl.188S_bib157","doi-asserted-by":"crossref","first-page":"15467","DOI":"10.1016\/S0021-9258(18)66735-3","article-title":"Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa","volume":"261","author":"Danielsson","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib158","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0021-9258(19)68378-X","article-title":"Heparin with two binding sites for antithrombin or platelet factor 4","volume":"257","author":"Jordan","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib159","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib160","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","article-title":"Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin and eliciting high anti-factor Xa activity","volume":"116","author":"Choay","year":"1983","journal-title":"Biochem Biophys Res Comm"},{"key":"10.1378\/chest.126.3_suppl.188S_bib161","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00280041","article-title":"Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin","volume":"39","author":"Handeland","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib162","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-1002751","article-title":"Pharmacokinetic studies of standard UFH, and low molecular weight heparins in the rabbit","volume":"14","author":"Boneu","year":"1988","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib163","first-page":"129","article-title":"Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance","volume":"40","author":"Palm","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib164","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4065\/73.6.545","article-title":"Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions","volume":"73","author":"Litin","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1378\/chest.126.3_suppl.188S_bib165","first-page":"35","article-title":"Low molecular weight heparins: practical considerations","volume":"34","author":"Kessler","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib166","doi-asserted-by":"crossref","first-page":"33L","DOI":"10.1016\/S0002-9149(98)00111-8","article-title":"Monitoring of low-molecular- weight heparins","volume":"82","author":"Abbate","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib167","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-2712(18)30347-0","article-title":"Contemporary laboratory monitoring of low molecular weight heparins","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib168","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/ajcp\/103.5.642","article-title":"Monitoring the anticoagulant effects of a low molecular weight heparin preparation","volume":"103","author":"Kessler","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib169","first-page":"799","article-title":"College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban","volume":"122","author":"Laposata","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib170","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0038-1642507","article-title":"Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis","volume":"71","author":"Alhenc-Gelas","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib171","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-0038-1651032","article-title":"The relationship between antifactor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement","volume":"62","author":"Levine","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib175","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"key":"10.1378\/chest.126.3_suppl.188S_bib176","first-page":"202","article-title":"Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in postsurgical patients treated with either Logiparin or unfractionated heparin","volume":"56","author":"Bara","year":"1986","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib177","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0049-3848(91)90403-J","article-title":"Laboratory monitoring of the clinical effects of low molecular weight heparins","volume":"14S","author":"Walenga","year":"1991","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib178","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"key":"10.1378\/chest.126.3_suppl.188S_bib179","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0038-1642507","article-title":"Adjusted versus fixed doses of the low-molecular weight heparin Fragmin in the treatment of deep vein thrombosis","volume":"71","author":"Alhenc-Gelas","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib180","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1055\/s-0038-1648866","article-title":"Low molecular weight heparin therapy: is monitoring needed","volume":"72","author":"Boneu","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib181","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0049-3848(85)90244-0","article-title":"Comparative pharmacokinetics of low molecular weight heparin and unfractionated heparin after intravenous and subcutaneous administration","volume":"39","author":"Bara","year":"1985","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib182","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib183","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1067\/mcp.2002.127114","article-title":"The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers","volume":"72","author":"Sanderink","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.126.3_suppl.188S_bib184","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.188S_bib185","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/ajhp\/60.7.683","article-title":"Weight-based administration of dalteparin in obese patients","volume":"60","author":"Smith","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1378\/chest.126.3_suppl.188S_bib186","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy- weight\/obese patients with the LMWH tinzaparin: a pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib187","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib188","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bjs.4068","article-title":"Enoxaparin effect depends on body- weight and current doses may be inadequate in obese patients","volume":"90","author":"Frederiksen","year":"2003","journal-title":"Br J Surg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib189","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.CCM.0000059725.60509.A0","article-title":"Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?","volume":"31","author":"Priglinger","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0049-3848(02)00188-3","article-title":"Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis","volume":"106","author":"Heizmann","year":"2002","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib191","first-page":"977","article-title":"Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery","volume":"73","author":"Samana","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib192","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1381\/096089202321144522","article-title":"A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery","volume":"12","author":"Scholten","year":"2002","journal-title":"Obes Surg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib193","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1381\/09608920160558588","article-title":"Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial","volume":"11","author":"Kalfarentzos","year":"2001","journal-title":"Obes Surg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib194","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1614119","article-title":"Elderly patients treated with tinzaparin administered once daily (175anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1592\/phco.21.2.169.34113","article-title":"The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease","volume":"21","author":"Brophy","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.188S_bib196","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000186641","article-title":"Pharmacokinetics of a low molecular weight heparin (fraxiparin) in various stages of chronic renal failure","volume":"59","author":"Goudable","year":"1991","journal-title":"Nephron"},{"key":"10.1378\/chest.126.3_suppl.188S_bib197","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0049-3848(91)90141-I","article-title":"Delayed elimination of enoxaparin in patients with chronic renal insufficiency","volume":"63","author":"Cadroy","year":"1991","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib198","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","article-title":"Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes","volume":"143","author":"Becker","year":"2002","journal-title":"Am Heart J"},{"key":"10.1378\/chest.126.3_suppl.188S_bib199","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270003253420","article-title":"Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin","volume":"43","author":"Chow","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink","year":"2002","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib201","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","article-title":"Aging and venous thromboembolism influence the pahrmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)","volume":"79","author":"Mismetti","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib202","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","article-title":"Is impaired renal function a contraindication to the use of low-molecular-weight heparin?","volume":"162","author":"Nagge","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.126.3_suppl.188S_bib203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200326030-00005","article-title":"Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients","volume":"26","author":"Cestac","year":"2003","journal-title":"Drug Saf"},{"key":"10.1378\/chest.126.3_suppl.188S_bib204","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.20.9.771.35210","article-title":"Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency","volume":"20","author":"Gerlach","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.126.3_suppl.188S_bib205","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-2007-1004373","article-title":"Biochemical and pharmacologic studies on the protamine interactions with heparin, it's fractions and fragments","volume":"11","author":"Racanelli","year":"1985","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-3848(87)90343-4","article-title":"Protamine reversal of anticoagulation achieved with a low molecular weight heparin: the effects on eicosanoids, clotting and complement factors","volume":"48","author":"Lindblad","year":"1987","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib207","first-page":"139","article-title":"Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate:in vitroandin vivostudy during cardiac surgery with extracorporeal circulation","volume":"16","author":"Massonnet-Castel","year":"1986","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.188S_bib208","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0038-1653794","article-title":"Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man","volume":"73","author":"Woltz","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib209","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/abio.1998.2947","article-title":"Determination of low-molecular-weight heparins and their binding to protamine and a protamine analog using polyion-sensitive membrane electrodes","volume":"266","author":"Ramamurthy","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1378\/chest.126.3_suppl.188S_bib210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0038-1645207","article-title":"Neutralization of enoxaparine-induced bleeding by protamine sulfate","volume":"63","author":"Van Ryn-McKenna","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib211","first-page":"155","article-title":"Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate","volume":"21","author":"Bang","year":"1991","journal-title":"Haemostasis"},{"key":"10.1378\/chest.126.3_suppl.188S_bib212","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-003-0633-1","article-title":"Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin","volume":"82","author":"Ng","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1378\/chest.126.3_suppl.188S_bib213","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0741-5214(05)80016-3","article-title":"Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine","volume":"21","author":"Wakefield","year":"1995","journal-title":"J Vasc Surg"},{"key":"10.1378\/chest.126.3_suppl.188S_bib214","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0049-3848(98)00201-1","article-title":"Low molecular weight protamine: a potential nontoxic heparin antagonist","volume":"94","author":"Byun","year":"1999","journal-title":"Thromb Res"},{"key":"10.1378\/chest.126.3_suppl.188S_bib215","first-page":"153","article-title":"Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model","volume":"47","author":"Hulin","year":"1997","journal-title":"Lab Anim Sci"},{"key":"10.1378\/chest.126.3_suppl.188S_bib216","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1006\/jsre.1996.0261","article-title":"A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation","volume":"63","author":"Wakefield","year":"1996","journal-title":"J Surg Res"},{"issue":"suppl","key":"10.1378\/chest.126.3_suppl.188S_bib217","first-page":"43","article-title":"Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine","volume":"25","author":"Dietrich","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.126.3_suppl.188S_bib172","unstructured":"Deleted in proof"},{"key":"10.1378\/chest.126.3_suppl.188S_bib173","unstructured":"Deleted in proof"},{"key":"10.1378\/chest.126.3_suppl.188S_bib174","unstructured":"Deleted in proof"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215314914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:51:01Z","timestamp":1757919061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215314914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":217,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0012369215314914"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.188s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heparin and Low-Molecular-Weight Heparin","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.126.3_suppl.188S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}